Skip Navigation



Rheumatology Advance Access published online on May 31, 2005
Rheumatology, doi:10.1093/rheumatology/keh698
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/9/1161    most recent
keh698v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kahles, T.
Right arrow Articles by Lindhoff-Last, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kahles, T.
Right arrow Articles by Lindhoff-Last, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received December 29, 2004
Accepted April 29, 2005

Original Papers

Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke

T. Kahles 1*, M. Humpich 2, H. Steinmetz 1, M. Sitzer 1, and E. Lindhoff-Last 3

1 Department of Neurology, Division of Angiology, University Hospital, JW Goethe University Frankfurt, Germany
2 Department of Neurology, Division of Angiology, University Hospital, JW Goethe University Frankfurt, Germany; Department of Internal Medicine, Division of Angiology, University Hospital, JW Goethe University Frankfurt, Germany
3 Department of Internal Medicine, Division of Angiology, University Hospital, JW Goethe University Frankfurt, Germany

* To whom correspondence should be addressed.
T. Kahles, E-mail: t.kahles{at}em.uni-frankfurt.de


  Abstract

Objective. Antiphospholipid antibodies (APLA) are established risk factors for venous thrombosis but their role in the pathogenesis of cerebral ischaemia is unclear. The purpose of the present study was to evaluate the relevance of various APLA in patients with cryptogenic stroke (group A, n = 21) and determined causes of stroke (group B, n = 104) according to the TOAST classification in comparison with healthy volunteers without any thrombotic or ischaemic event in their history (group C, n = 84).

Methods. Median ages were 52 yr (A), 60 yr (B) and 51 yr (C). Blood samples were tested for lupus anticoagulant (LA) using phospholipid-dependent coagulation tests (activated partial thromboplastin time, diluted Russell viper venom time). Confirmatory tests were performed if necessary. Furthermore, we assessed the presence of specific APLA and their antibody subclasses against cardiolipin (AclA), phosphatidylserine (ApsA), phosphatidylinositol (ApiA) and beta-2-glycoprotein I (A{beta}2A) using enzyme-linked immunosorbent assay.

Results. For ApsA IgG we found a significantly higher prevalence in stroke patients (57.7%) compared with normal subjects (4.8%; P<0.001). Similarly, A{beta}2A IgA was significantly more prevalent in stroke patients (20.8%) in comparison with normals (3.6%; P<0.001). For all other APLAs tested, no significant differences emerged after adjustment for multiple comparisons. We did not find significant differences between stroke subtypes for any APLA.

Conclusion. The results of this study suggest a relevant role for antiphosphatidylserine IgG and anti-{beta}2-glycoprotein I IgA in stroke aetiology.

Keywords: Ischaemic stroke; Phospholipid antibodies; Lupus anticoagulant; Anti-{beta}2-GP I; Antiphosphatidylserine.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
T. Kahles, M. Humpich, M. Sitzer, and E. Lindhoff-Last
{beta}2-Glycoprotein I IgA antibodies and ischaemic stroke: reply
Rheumatology, May 1, 2006; 45(5): 646 - 646.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. L. Staub, C. A. von Muhlen, and G. L. Norman
{beta}2-Glycoprotein I IgA antibodies and ischaemic stroke
Rheumatology, May 1, 2006; 45(5): 645 - 646.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.